Glenmark Pharmaceuticals (GLENMARK) Share Price Falls 2.41% as Valuation Stays Above Sector Median
- September 9, 2026
- Posted by: Kunal Singla
- Category: News
Glenmark Pharmaceuticals Share Price fell to Rs 2,231.65, down 2.41% from the previous close, while market capitalisation stood at Rs 64,599.82 crore. As of 08 October 2026 at 12:23:01 PM IST, the move places Glenmark Pharmaceuticals Share Price back under the prior session’s finish, with the intraday range showing a touch of Rs 2,283 and a low of Rs 2,230.9. For readers tracking Glenmark Pharmaceuticals Share Price Today, the day’s decline is relevant because it combines a lower quoted price with a market value that still places the company in Large Cap territory. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. The latest Univest figures therefore make Glenmark Pharmaceuticals Share Price a clear stock news item for investors following healthcare, valuation and relative positioning.
The latest Univest figures also show that Glenmark Pharmaceuticals Share Price remains a useful case study for Glenmark Pharmaceuticals Stock News and Glenmark Pharmaceuticals Share Price Fall searches because the decline is measurable, the fundamentals are available, and the healthcare peer set gives context without requiring speculation.
Glenmark Pharmaceuticals (GLENMARK) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,231.65 |
| Previous Close | Rs 2,286.75 |
| Today's Move | -Rs 55.10 (-2.41%) |
| Open | Rs 2,282.95 |
| High | Rs 2,283 |
| Low | Rs 2,230.9 |
| Market Capitalisation | Rs 64,599.82 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Share Price Today opened at Rs 2,282.95, moved to Rs 2,283 at the high, and touched Rs 2,230.9 at the low before trading at Rs 2,231.65 at 08 October 2026 at 12:23:01 PM IST. The day change was Rs -55.1, or -2.41%, versus the previous close of Rs 2,286.75. That puts Glenmark Pharmaceuticals Share Price below the prior session reference, with the latest move occurring inside a tight intraday band of just over Rs 52. The market capitalisation of Rs 64,599.82 crore keeps Glenmark Pharmaceuticals Share Price in Large Cap company-size context. For readers watching Glenmark Pharmaceuticals Share Price Live, the session shows a clear price fall without any need to stretch beyond the exact numbers. Glenmark Pharmaceuticals Share Price Today remains one of the key stock price updates in healthcare this morning, and the next layer of analysis is the fundamental profile behind the move.
Glenmark Pharmaceuticals (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 64,599.82 crore |
| P/E Ratio | 35.9x |
| P/B Ratio | 5.89x |
| ROE | 14.1% |
| ROCE | 20.35% |
| EPS | Rs 63.7 |
| Book Value Per Share | Rs 388.43 |
| Dividend Yield | 0.11% |
Glenmark Pharmaceuticals (GLENMARK) fundamental metrics show P/E 35.9x, P/B 5.89x, ROE 14.1%, ROCE 20.35%. These figures provide context only and are not a buy or sell signal.
Glenmark Pharmaceuticals has a market capitalisation of Rs 64,599.82 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 35.9x, P/B at 5.89x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 63.7, book value per share of Rs 388.43, dividend yield of 0.11%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.87x, median ROE of 11.61%, median ROCE of 13.46%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 35.9x |
| Benchmark Median P/E | 31.87x |
| Benchmark Average P/E | 48.48x |
| Benchmark P/E Range | 3.58x to 708.87x |
| Company P/B Ratio | 5.89x |
| Benchmark Median P/B | 2.98x |
| Benchmark Average P/B | 4.31x |
| Company ROE | 14.1% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 20.35% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 64,599.82 crore |
| Benchmark Median Market Cap | Rs 854.81 crore |
| Benchmark Average Market Cap | Rs 14,121.7 crore |
Glenmark Pharmaceuticals (GLENMARK) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Glenmark Pharmaceuticals (GLENMARK) has a P/E ratio of 35.9x, which is above the benchmark median of 31.87x, a difference of +12.65%. On its own, the P/E gap is a valuation reference point, not a trading call.
Glenmark Pharmaceuticals (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.61%, a difference of +21.45%. Glenmark Pharmaceuticals (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 13.46%, a difference of +51.19%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,32,120.23 | 35.37 | 4.95 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,53,389.76 | 86.95 | 14.4 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,81,739.76 | 82.14 | 19.96 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,710.44 | 25.51 | 4.27 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,10,980.13 | 101.55 | 19.69 | 18.31 | 18.2 |
Glenmark Pharmaceuticals (GLENMARK) has a P/E ratio of 35.9x compared with the displayed peer median of 82.14x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 14.1% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of Rs 64,599.82 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Share Price is down 2.41% today, which keeps the stock in active price-action focus.
- The previous close of Rs 2,286.75 versus a trade at Rs 2,231.65 gives a clear intraday reference for Glenmark Pharmaceuticals Share Price Today.
- ROE of 14.1% and ROCE of 20.35% keep Glenmark Pharmaceuticals Fundamental Analysis relevant.
- P/E of 35.9 and P/B of 5.89 show that Glenmark Pharmaceuticals Share Price is not trading at a low valuation versus the industry median.
- Healthcare sector benchmark data gives context for Glenmark Pharmaceuticals Share Price News and peer comparison.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals operates in Healthcare, within Pharmaceuticals & Drugs. The company’s business sits in a sector where investors usually compare earnings, capital returns, book value and valuation alongside peer positioning. Glenmark Pharmaceuticals Share Price therefore attracts attention not only as a live quote but also as a reflection of how the market reads its business profile versus other large listed pharmaceutical companies. The latest Univest figures show a company with Large Cap status, a meaningful market presence and valuation metrics that can be read alongside sector norms.
Track Glenmark Pharmaceuticals Share Price on Univest
Use Glenmark Pharmaceuticals (GLENMARK) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Glenmark Pharmaceuticals Share Price on Univest for live price updates, valuation ratios, 52-week levels and market insights. The platform also helps readers compare Glenmark Pharmaceuticals Share Price with healthcare peers and understand Glenmark Pharmaceuticals Stock News in one place. For investors following Glenmark Pharmaceuticals Share Price Today, Univest keeps the core numbers together for quick review.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Glenmark Pharmaceuticals Share Price falling today?
Ans. Glenmark Pharmaceuticals Share Price is down 2.41% today to Rs 2,231.65 from Rs 2,286.75. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. The intraday range extended from Rs 2,230.9 to Rs 2,283.
What is Glenmark Pharmaceuticals Share Price Today?
Ans. Glenmark Pharmaceuticals Share Price Today is Rs 2,231.65 as of 08 October 2026 at 12:23:01 PM IST. The stock is trading below the previous close after opening at Rs 2,282.95.
What is Glenmark Pharmaceuticals market capitalisation?
Ans. Glenmark Pharmaceuticals has a market capitalisation of Rs 64,599.82 crore. That keeps Glenmark Pharmaceuticals Share Price in Large Cap company-size context and well above the median market cap for the same-industry benchmark.
How does Glenmark Pharmaceuticals valuation compare with peers?
Ans. Glenmark Pharmaceuticals Share Price trades at a P/E of 35.9 and P/B of 5.89. That is above the sector median P/E of 31.87 and P/B of 2.98, while still below some high-multiple peers.
What do ROE and ROCE show for Glenmark Pharmaceuticals Share Price?
Ans. Glenmark Pharmaceuticals reports ROE of 14.1% and ROCE of 20.35%. Both are above the sector medians in the same-industry benchmark, which adds context to Glenmark Pharmaceuticals Fundamental Analysis. The previous close was Rs 2,286.75.
What does EPS mean for Glenmark Pharmaceuticals?
Ans. Glenmark Pharmaceuticals EPS is Rs 63.7. EPS shows earnings attributable to each share, so it is one of the key metrics used alongside Glenmark Pharmaceuticals Share Price when reading company valuation.
What does book value per share mean here?
Ans. Glenmark Pharmaceuticals book value per share is Rs 388.43. Book value shows the accounting net worth behind each share, and it helps investors compare Glenmark Pharmaceuticals Share Price with its asset base.
Does Glenmark Pharmaceuticals pay a dividend?
Ans. Glenmark Pharmaceuticals has a dividend yield of 0.11%. Dividend yield is the historical payout relative to the current price, so it is a useful context point when reviewing Glenmark Pharmaceuticals Share Price.
What sector does Glenmark Pharmaceuticals belong to?
Ans. Glenmark Pharmaceuticals operates in Healthcare, within the Pharmaceuticals & Drugs industry. That is the correct frame for comparing Glenmark Pharmaceuticals Share Price with the listed peer group and sector benchmark.